Predictive value of biomarkers for lenvatinib in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a highly lethal disease that exhibits a rising global incidence, and most HCC patients are at an advanced stage at the time of diagnosis. Although lenvatinib has become the first-line option for HCC and its overall survival is not inferior to sorafenib, not all HCC...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-08-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359251363102 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849232814857256960 |
|---|---|
| author | Xiangyong Hao Zihan Li Xin Su Jian Li Youbao Ye Cailiu Wang Xiao Xu Hao Song Baoling Song Xiang Lan Tian Luo |
| author_facet | Xiangyong Hao Zihan Li Xin Su Jian Li Youbao Ye Cailiu Wang Xiao Xu Hao Song Baoling Song Xiang Lan Tian Luo |
| author_sort | Xiangyong Hao |
| collection | DOAJ |
| description | Hepatocellular carcinoma (HCC) is a highly lethal disease that exhibits a rising global incidence, and most HCC patients are at an advanced stage at the time of diagnosis. Although lenvatinib has become the first-line option for HCC and its overall survival is not inferior to sorafenib, not all HCC patients could derive benefits from lenvatinib. Therefore, it was urgent to predict which group of HCC patients could derive benefits from lenvatinib and monitor its therapeutic effectiveness during treatment. This review summarized various biomarkers that could be used for prediction of lenvatinib response, including 7 biomarkers that are applied in clinical practice, 11 biomarkers that are applied in clinical practice, and 6 biomarkers that are under exploratory stage. By conducting this first comprehensive analysis of predictive biomarkers for lenvatinib in HCC patients, this review aims to help doctors to assess the response of lenvatinib treatment more accurately and, thus, develop more effective individualized treatment plans. |
| format | Article |
| id | doaj-art-2e7fa7e1090e4823a8dc3ca32a341f54 |
| institution | Kabale University |
| issn | 1758-8359 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj-art-2e7fa7e1090e4823a8dc3ca32a341f542025-08-20T18:03:32ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592025-08-011710.1177/17588359251363102Predictive value of biomarkers for lenvatinib in hepatocellular carcinomaXiangyong HaoZihan LiXin SuJian LiYoubao YeCailiu WangXiao XuHao SongBaoling SongXiang LanTian LuoHepatocellular carcinoma (HCC) is a highly lethal disease that exhibits a rising global incidence, and most HCC patients are at an advanced stage at the time of diagnosis. Although lenvatinib has become the first-line option for HCC and its overall survival is not inferior to sorafenib, not all HCC patients could derive benefits from lenvatinib. Therefore, it was urgent to predict which group of HCC patients could derive benefits from lenvatinib and monitor its therapeutic effectiveness during treatment. This review summarized various biomarkers that could be used for prediction of lenvatinib response, including 7 biomarkers that are applied in clinical practice, 11 biomarkers that are applied in clinical practice, and 6 biomarkers that are under exploratory stage. By conducting this first comprehensive analysis of predictive biomarkers for lenvatinib in HCC patients, this review aims to help doctors to assess the response of lenvatinib treatment more accurately and, thus, develop more effective individualized treatment plans.https://doi.org/10.1177/17588359251363102 |
| spellingShingle | Xiangyong Hao Zihan Li Xin Su Jian Li Youbao Ye Cailiu Wang Xiao Xu Hao Song Baoling Song Xiang Lan Tian Luo Predictive value of biomarkers for lenvatinib in hepatocellular carcinoma Therapeutic Advances in Medical Oncology |
| title | Predictive value of biomarkers for lenvatinib in hepatocellular carcinoma |
| title_full | Predictive value of biomarkers for lenvatinib in hepatocellular carcinoma |
| title_fullStr | Predictive value of biomarkers for lenvatinib in hepatocellular carcinoma |
| title_full_unstemmed | Predictive value of biomarkers for lenvatinib in hepatocellular carcinoma |
| title_short | Predictive value of biomarkers for lenvatinib in hepatocellular carcinoma |
| title_sort | predictive value of biomarkers for lenvatinib in hepatocellular carcinoma |
| url | https://doi.org/10.1177/17588359251363102 |
| work_keys_str_mv | AT xiangyonghao predictivevalueofbiomarkersforlenvatinibinhepatocellularcarcinoma AT zihanli predictivevalueofbiomarkersforlenvatinibinhepatocellularcarcinoma AT xinsu predictivevalueofbiomarkersforlenvatinibinhepatocellularcarcinoma AT jianli predictivevalueofbiomarkersforlenvatinibinhepatocellularcarcinoma AT youbaoye predictivevalueofbiomarkersforlenvatinibinhepatocellularcarcinoma AT cailiuwang predictivevalueofbiomarkersforlenvatinibinhepatocellularcarcinoma AT xiaoxu predictivevalueofbiomarkersforlenvatinibinhepatocellularcarcinoma AT haosong predictivevalueofbiomarkersforlenvatinibinhepatocellularcarcinoma AT baolingsong predictivevalueofbiomarkersforlenvatinibinhepatocellularcarcinoma AT xianglan predictivevalueofbiomarkersforlenvatinibinhepatocellularcarcinoma AT tianluo predictivevalueofbiomarkersforlenvatinibinhepatocellularcarcinoma |